Jefferies Increases Price Target in Biogen (BIIB)

May 2, 2012 2:47 PM EDT
Get Alerts BIIB Hot Sheet
Price: $209.15 -0.32%

Rating Summary:
    28 Buy, 15 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Jefferies analysts updated their price target on Biogen Idec (NASDAQ: BIIB), raising it by $17 to $154 from $137.

Biogen IDEC is a biotechnology company focused on developing, manufacturing and commercializing biologic drugs primarily for inflammatory/autoimmune diseases and cancer.

Sales of one of BIIB’s drugs, Avonex, were impacted by one-time factors resulting in sales that were lower than estimates in the first quarter. Analysts don’t expect these factors to influence future performance. Additionally, Jefferies analysts see strong positives for Tysabri, including trends in net patient adds, use in newly diagnosed patients, and low discontinuations.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $131.83 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, Raising Prices